Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monotherapy MORAb-004 in Metastatic Melanoma
2011-001282-40Phase 2Completed
- Sponsor
- Morphotek
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of ontuxizumab in melanoma (2 arms), sponsored by Morphotek. Primary endpoints: Progression-free survival at 24 weeks and Optimal biological dose determination. Started May 2011; status: completed.
02
Drugs
ontuxizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-001282-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001282-40.